Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00164450
Status:
COMPLETED
Last Update Posted:
2008-08-25
First Post:
2005-09-10
Brief Title:
TBTC Study 26 PK Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection
Sponsor:
Centers for Disease Control and Prevention
Organization:
Centers for Disease Control and Prevention
Study Overview
Official Title:
TBTC Study 26 PK Rifapentine Pharmacokinetics in Children Receiving Once Weekly Rifapentine and Isoniazid for the Treatment of Latent Tuberculosis Infection
Status:
COMPLETED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Compared to adults children appear to require higher weight-based doses of rifapentine to acheive comparable drug levels TBTC Study 26 a study of the effectiveness and tolerability of weekly rifapentineisoniazid for three months versus daily isoniazid for nine months for the treatment of latent tuberculosis infection has been amended to include children ages 2-11 based on an initial single-dose study and pharmacokinetic modeling Study 26PK evaluates the adequacy of the doses chosen for young children enrolled in Study 26 with a single blood draw 24 hours after the third or subsequent weekly Study 26 dose of rifapentine and isoniazid An adult control is enrolled for each child enrolled
Detailed Description:
The pharmacokinetics of rifapentine have been studied in adults adolescents ages 12-15 years and patients with hepatic dysfunction and HIV infection However there are no published data on the efficacy safety or pharmacokinetics of rifapentine in children This lack of data has precluded till now enrollment of children less than 12 years old in TBTC Study 26 a study of the effectiveness and tolerability of weekly rifapentineisoniazid for three months versus daily isoniazid for nine months for the treatment of latent tuberculosis infection a phase 3 treatment trial that will enroll 8000 persons with latent tuberculosis infection A recently completed initial evaluation of rifapentine pharmacokinetics among children receiving a single dose of rifapentine demonstrated significantly lower exposures of rifapentine among children compared to adults when children were given weight-based doses chosen to be comparable to a 600 mg oral dose in adults This reduced exposure suggested that children require higher weight-based doses than adults and a model was constructed to estimate rifapentine doses in children that would result in exposures similar to the 900 mg dose used for adults in Study 26 Study 26 has been amended to include children ages 2-11 based on the initial single-dose study and pharmacokinetic modeling The purpose of Study 26PK is to evaluate the adequacy of the doses chosen for young children who enrolled in Study 26
Briefly this study aims to
determine whether rifapentine exposure is equivalent in young children receiving weight-based dosing to adults receiving 900 mg
correlate rifapentine exposure with toxicity in young children
validate accuracy of weight-based dosing in children
determine rifapentine bioavailability in children
determine association in adults between polymorphisms of MDR1 genotype and rifapentine exposure
correlate isoniazid concentrations in adults with acetylator status
Briefly this study aims to
determine whether rifapentine exposure is equivalent in young children receiving weight-based dosing to adults receiving 900 mg
correlate rifapentine exposure with toxicity in young children
validate accuracy of weight-based dosing in children
determine rifapentine bioavailability in children
determine association in adults between polymorphisms of MDR1 genotype and rifapentine exposure
correlate isoniazid concentrations in adults with acetylator status
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None